Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule cancer therapies designed to alter how existing cancer drugs are metabolized or distributed in the body. Its oncology pipeline includes NGC-Cap, a combination of PCS6422 and a lower dose of capecitabine, which is in a Phase 2 trial for advanced or metastatic breast cancer, and NGC-Iri, an analog of irinotecan’s active metabolite that is in preclinical development. Processa also has two non-oncology drug candidates: PCS12852 for gastroparesis and PCS499 for primary glomerular diseases. It is exploring licensing or partnership options for these assets. Processa conducts drug development and seeks to advance candidates through clinical studies and regulatory review. Its principal executive office is in Vero Beach, Florida.
No SEC Form 4 filings for $PCSA in the last 30 days.
See all $PCSA insider activity →Processa Pharmaceuticals, Inc. (PCSA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics • U.S. FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria ; additional Phase 2 studies planned in food allergy and relapsing multi
Processa Pharmaceuticals (PCSA) received FDA clearance for a Phase 2 study of VT-7208 in chronic spontaneous urticaria. The company also expanded its pipeline through a research collaboration with Generian Pharmaceuticals and appointed Sheila Gujrathi, M.D., as Executive Chair. Processa raised $200M and expects its cash runway to extend into the second half of 2029.
Processa Pharmaceuticals (Nasdaq: PCSA) completed a July 2026 acquisition of Vidya Therapeutics, adding CNS-penetrant BTK inhibitor VT-7208 and shifting focus to immune-mediated diseases. Vidya holders received about 46% and private placement investors about 52.6%, leaving prior Processa holders about 0.9%. A $200M private placement funds operations into 2H 2029; Phase II starts planned in 2H 2026 (food allergy, CSU) and 1H 2027 (RMS).
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning PCSA (Processa Pharmaceuticals, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent PCSA coverage spans mergers & acquisitions, regulation and insider activity.
Positive regulatory milestone and substantial new capital likely boost investor sentiment.
Positive regulatory approval reduces clinical risk and may boost investor sentiment.
The deal and financing materially reset Processa’s risk profile toward VT-7208, with Phase II timelines in food allergy, CSU, and RMS.
The 8-K is a corporate governance and equity-compensation update, not an operating or clinical catalyst. It can modestly affect dilution expectations and near-term sentiment around SBC.
Acquisition plus sizable financing can accelerate development, but also raises dilution and execution risk.
AlphAI scores every news story that mentions PCSA with an AI model for sentiment and relevance, and aggregates insider trades from Processa Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Processa Pharmaceuticals, Inc. (PCSA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics • U.S. FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria ; additional Phase 2 studies planned in food allergy and relapsing multi
2 min readProcessa Pharmaceuticals (PCSA) received FDA clearance for a Phase 2 study of VT-7208 in chronic spontaneous urticaria. The company also expanded its pipeline through a research collaboration with Generian Pharmaceuticals and appointed Sheila Gujrathi, M.D., as Executive Chair. Processa raised $200M and expects its cash runway to extend into the second half of 2029.
1 min readProcessa Pharmaceuticals (Nasdaq: PCSA) completed a July 2026 acquisition of Vidya Therapeutics, adding CNS-penetrant BTK inhibitor VT-7208 and shifting focus to immune-mediated diseases. Vidya holders received about 46% and private placement investors about 52.6%, leaving prior Processa holders about 0.9%. A $200M private placement funds operations into 2H 2029; Phase II starts planned in 2H 2026 (food allergy, CSU) and 1H 2027 (RMS).
6 min readProcessa Pharmaceuticals, Inc. (PCSA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 30, 2026, Processa Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders (the “Annual
3 min readThe healthcare sector saw multiple company-specific moves. Pfizer and BioNTech received EU approval for an updated COVID-19 vaccine targeting the XFG variant. Cipla won FDA approval for generic Advair Diskus, and Viatris gained FDA approval for its Gwyn Lo contraceptive patch. AbbVie’s Rinvoq was approved in the EU for non-segmental vitiligo. Boston Scientific announced an $800M restructuring plan, while GSK launched a $2.5B cost-saving program. J&J and Sail agreed a $3.51B CAR-T deal; Argenx ac
7 min readThe acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.
6 min readProcessa Pharmaceuticals (PCSA) will acquire privately held Vidya Therapeutics and raise about $200M via a private financing. Vidya’s lead candidate VT-7208 is a CNS-penetrant BTK inhibitor for food allergy, CSU, and RMS. Deal terms include 558,398 PCSA shares plus preferred shares; financing priced at $1,221.19/share. Expected close July 30, 2026; PCSA stock fell 38% to $1.88.
4 min readProcessa Pharmaceuticals, Inc. (PCSA) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS ● Acquisition brings into Processa’s pipeline Vidya’s lead asset,
2 min readGuy Wendy (Chief Administrative Officer) purchased 2,436 shares of Processa Pharmaceuticals, Inc. (PCSA) at $1.93 on 2026-06-30.
2 min readLin Patrick (Chief Business - Strategy Off) purchased 2,106 shares of Processa Pharmaceuticals, Inc. (PCSA) at $1.93 on 2026-06-30.
2 min read
